Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMVP Health Care Lyfgenia Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentMVP Health CarePolicy N/A

    Medicare Part B: Lyfgenia (Lovotibeglogene Autotemcel)

    Customize your policy alerts

    Sign up for all MVP Health Care policy alerts

    Know when MVP Health Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Medicare Part B coverage and prior authorization for Lyfgenia, a one-time gene therapy for members aged 12 years or older with sickle cell disease and recurrent vaso-occlusive crises. Coverage requires specified clinical documentation, treatment at a Qualified Treatment Center, and fulfillment of hematologic, organ-function, infection, and transplant-related criteria.

    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: Lyfgenia (Lovotibeglogene Autotemcel)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateSep 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation demonstrating that all clinical, treatment-history, transplant, organ-function, pregnancy, infection, prescriber, and site-of-care criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12+Minimum member age
    ≥4Severe crises required before screening
    1 doseMaximum treatment course
    6 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Approval window
    Qualified Treatment CenterAdministration setting

    Coverage Criteria

    Initial Clinical Eligibility

    Lyfgenia is covered for sickle cell disease with recurrent vaso-occlusive crises when ALL of the following criteria are met:

    ALL of the following

    • Prescribed by a board-certified hematologist.
    • Chart notes document a diagnosis of sickle cell disease (SCD) with βS/βS, βS/β0, or βS/β+ genotype.
    • Member is at least 12 years old.>= 12 years
    • Chart notes document at least 4 severe vaso-occlusive crises in the 2 years prior to screening while adhering to previous SCD therapy.>= 4 severe crises in prior 2 years

      Severe vaso-occlusive crises include an episode of acute pain with no medically determined cause other than vaso-occlusion lasting more than 2 hours; acute chest syndrome; acute hepatic sequestration; acute splenic sequestration; a vaso-occlusive episode requiring hospitalization or multiple emergency department/urgent care visits over 72 hours with intravenous medications at each visit; or priapism requiring any level of medical attention.

    Prior Therapy and Transplant Eligibility

    Coverage requires documentation that ALL of the following prior-therapy and transplant criteria are met:

    ALL of the following

    • Member has not received a prior allogeneic or autologous hematopoietic stem cell (HSC) transplant.
    • Member is not being considered for other gene or investigational therapies for SCD.
    • Member has failed to match with a hematopoietic stem cell donor.
    • Chart notes document that the member has tried and failed other SCD treatment, such as hydroxyurea, Adakveo, Oxbryta, or Endari, up to the maximally indicated dose for at least 6 months.>= 6 months

      Documentation must include dates of use.

    Safety and Laboratory Criteria

    Coverage requires documentation that ALL of the following safety and laboratory criteria are met:

    ALL of the following

    • Member does not have advanced renal impairment, documented with current renal function testing.

      Renal impairment is defined as creatinine clearance ≤ 70 mL/min/1.73 m².

    • Member does not have advanced liver impairment, documented with current liver function testing.

      Examples of advanced liver impairment include alanine transaminase > 3 times the upper limit of normal, direct bilirubin > 2.5 times the upper limit of normal, baseline prothrombin time (INR) > 1.5 times the upper limit of normal, cirrhosis, bridging fibrosis, or active hepatitis.

    • For female members, a negative serum pregnancy test is confirmed.
    • Current screening is negative for HIV-1 and HIV-2, with documentation that the member does not have active HIV-1 or HIV-2.

    Administration and Approval Window

    Lyfgenia administration and approval are subject to ALL of the following conditions:

    ALL of the following

    • Lyfgenia is administered at a Qualified Treatment Center.

      See the LYFGENIA™ (lovotibeglogene autotemcel) Qualified Treatment Center Locator for treatment centers.

    • Lyfgenia is approved as a one-time dose within 6 months.One-time dose; within 6 months
    • Member remains eligible at the time of infusion.

      Coverage is contingent on eligibility at the time of infusion.

    • Requests for replacement due to lost or damaged product are not covered.

    Coverage exclusions: Age, dose, frequency of dosing, and/or duration of therapy outside FDA-approved package labeling; use in combination with other autologous genome-edited hematopoietic stem cell-based gene therapies such as Casgevy; renal deficiency; hepatic deficiency; pregnancy or plans to become pregnant; not being an appropriate candidate for hematopoietic stem cell transplantation; prior allogeneic or autologous HSC transplant; positive or active HIV-1 or HIV-2; active bacterial, viral, fungal, or parasitic infections; or more than two α-globin gene deletions.

    Coding and Coverage Parameters

    Drugs Requiring Prior Authorization under the medical benefitHCPCS
    J3394Lyfgenia (Lovotibeglogene Autotemcel)
    Minimum age
    Minimum ageAt least 12 years old
    Applicable treatmentLyfgenia for sickle cell disease with recurrent vaso-occlusive crises
    Prescriber requirementPrescribed by a board-certified hematologist
    Recurrent severe vaso-occlusive crises
    Required frequencyAt least 4 severe vaso-occlusive crises
    Look-back periodDuring the 2 years before screening
    Treatment context

    Provider Requirements and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required under the medical benefit before Lyfgenia (lovotibeglogene autotemcel) is administered. Submit documentation demonstrating that all clinical, treatment-history, transplant-candidacy, safety, and administration requirements are met.

    • Drug: J3394 Lyfgenia (lovotibeglogene autotemcel).
    • Prescribed by a board-certified hematologist.
    • Administered at a Qualified Treatment Center.
    • Member is at least 12 years old and meets FDA-approved package-label parameters for age, dose, frequency, and duration.
    • Coverage is for a one-time dose within 6 months, subject to continued eligibility at the time of infusion.
    Step Therapy

    Failure of Prior SCD Therapy

    Document that the member has tried and failed appropriate prior sickle cell disease treatment before Lyfgenia is requested.

    Therapy Background

    Lyfgenia is a one-time intravenous autologous hematopoietic stem cell-based gene therapy for sickle cell disease with recurrent vaso-occlusive crises. Treatment involves mobilization and apheresis to collect CD34-positive cells, myeloablative conditioning, ex-vivo transduction of the cells with a BB305 lentiviral vector encoding a modified beta-globin gene, and reinfusion of the modified cells. The modified cells engraft and produce red blood cells containing modified adult hemoglobin, which is intended to reduce hemoglobin S-related sickling and vaso-occlusive crises.

    Policy Definitions

    Vaso-occlusive crisis
    DefinitionA potentially life-threatening complication caused when sickled red blood cells hinder blood flow
    Clinical effectThe obstruction causes pain and reduces oxygen delivery to tissue
    Policy contextVaso-occlusive crises are associated with sickle cell disease and are the basis for Lyfgenia coverage consideration
    Severe vaso-occlusive crisis
    Acute painPain without another medically determined cause, lasting more than 2 hours
    Acute syndromesAcute chest syndrome, acute hepatic sequestration, or acute splenic sequestration
    Hospital or emergency care

    Initial Lyfgenia Therapy

    Initial Lyfgenia Therapy

    Initial coverage requires ALL of the following clinical, treatment-history, safety, and administration criteria.

    Initial Lyfgenia authorization

    • The member is at least 12 years old.Age ≥12 years
    • Lyfgenia is prescribed by a board-certified hematologist and administered at a Qualified Treatment Center.
    • Chart notes document sickle cell disease with βS/βS, βS/β0, or βS/β+ genotype.
    • The member has no more than two α-globin gene deletions.

      Lyfgenia has not been studied in members with more than two α-globin gene deletions.

    Prior Sickle Cell Disease Therapy

    StepRequirementDuration / documentation
    1
    Prior treatment with other sickle cell disease therapies, such as hydroxyurea, Adakveo, Oxbryta, or Endari
    Tried and failed at the maximally indicated dose for at least 6 months; documentation must include dates of use.

    Treatment Quantity

    Quantity limits
    DrugLyfgenia (lovotibeglogene autotemcel)
    Dose limitOne-time dose
    Administration windowThe dose must be administered within 6 months
    Replacement requestsRequests for replacement due to lost or damaged product are not covered
    Infusion eligibilityCoverage is contingent on eligibility at the time of infusion

    Administration Location

    Note

    Schedule infusion at a Qualified Treatment Center

    Lyfgenia must be administered at a Qualified Treatment Center.

    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: Lyfgenia (Lovotibeglogene Autotemcel)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateSep 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation demonstrating that all clinical, treatment-history, transplant, organ-function, pregnancy, infection, prescriber, and site-of-care criteria are met.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Coverage ParametersProvider Requirements and Denial RisksTherapy BackgroundPolicy DefinitionsInitial Lyfgenia TherapyPrior Sickle Cell Disease TherapyTreatment QuantityAdministration Location
    Provider attestation confirms that the member is an appropriate candidate for hematopoietic stem cell transplantation.
    Current documentation confirms that the member does not have any active bacterial, viral, fungal, or parasitic infection(s).
  1. Member has no more than two α-globin gene deletions.≤ 2 α-globin gene deletions

    Lyfgenia has not been studied in members with more than two α-globin gene deletions.

  2. Crises must occur while the member is adhering to previous sickle cell disease therapy
    Renal impairment
    Renal impairment thresholdCreatinine clearance ≤ 70 mL/min/1.73 m²
    Coverage requirementThe member must not have renal impairment at or below this threshold
    DocumentationCurrent renal function tests must be submitted
    Advanced liver impairment
    ALT> 3 times the upper limit of normal
    Direct bilirubin> 2.5 times the upper limit of normal
    Baseline PT/INR> 1.5 times the upper limit of normal
    Other qualifying conditionsCirrhosis, bridging fibrosis, or active hepatitis
    • Include trial and failure of treatments such as hydroxyurea, Adakveo, Oxbryta, or Endari, up to the maximally indicated dose for at least 6 months.
    • Include dates of use for each prior treatment.
    Documentation Required

    SCD History and Treatment Documentation

    Submit chart notes supporting the diagnosis, disease severity, treatment adherence, and prior treatment history for recurrent vaso-occlusive crises.

    • Document SCD with βS/βS, βS/β0, or βS/β+ genotype; Lyfgenia has not been studied in members with more than two α-globin gene deletions.
    • Member must be at least 12 years old.
    • Document at least 4 severe vaso-occlusive crises in the 2 years before screening while adhering to previous SCD therapy.
    • Qualifying events include acute pain lasting more than 2 hours without another medically determined cause; acute chest syndrome; acute hepatic or splenic sequestration; vaso-occlusive episodes requiring hospitalization or multiple emergency department/urgent-care visits over 72 hours with intravenous medication at each visit; or priapism requiring medical attention.
    • Document adherence to previous SCD therapy and the dates and outcomes of prior treatment trials.
    • Document failure to match with a hematopoietic stem cell donor.
    Documentation Required

    Transplant Candidacy and Competing Therapy Documentation

    Document transplant history and confirm that Lyfgenia is appropriate in relation to other potential SCD therapies.

    • Provide provider attestation that the member is an appropriate candidate for hematopoietic stem cell transplantation.
    • Confirm that the member has not received a prior allogeneic or autologous hematopoietic stem cell transplant.
    • Confirm that the member is not being considered for other gene or investigational therapies for SCD.
    • Lyfgenia may not be used in combination with another autologous genome-edited hematopoietic stem cell-based gene therapy, such as Casgevy.
    Documentation Required

    Renal and Hepatic Function

    Submit current renal and liver function documentation confirming that the member does not have advanced renal or hepatic impairment.

    • Renal impairment is defined as creatinine clearance ≤ 70 mL/min/1.73 m².
    • Advanced liver impairment includes alanine transaminase > 3 times the upper limit of normal, direct bilirubin > 2.5 times the upper limit of normal, baseline prothrombin time (INR) > 1.5 times the upper limit of normal, cirrhosis, bridging fibrosis, or active hepatitis.
    • Members with renal or hepatic deficiency are excluded from coverage.
    Documentation Required

    Pregnancy Testing

    For female members, confirm a negative serum pregnancy test before treatment.

    • Coverage is excluded when the member is pregnant or planning to become pregnant.
    Documentation Required

    Infection Screening

    Submit current infection screening and clinical documentation confirming that the member has no active infection.

    • Provide a current negative screening result for HIV-1 and HIV-2.
    • Documentation must indicate that the member does not have active HIV-1 or HIV-2.
    • Confirm absence of active bacterial, viral, fungal, or parasitic infection.
    Denial Risk

    Exclusion Conditions

    Coverage may be denied when Lyfgenia is requested outside approved parameters or when an exclusion applies.

    • Age, dose, frequency of dosing, or duration of therapy outside FDA-approved package labeling is excluded.
    • Use in combination with other autologous genome-edited hematopoietic stem cell-based gene therapies, such as Casgevy, is excluded.
    • Coverage is excluded for renal deficiency, hepatic deficiency, pregnancy or plans to become pregnant, or lack of candidacy for hematopoietic stem cell transplantation.
    • Coverage is excluded after a prior allogeneic or autologous hematopoietic stem cell transplant.
    • Coverage is excluded for positive or active HIV-1/HIV-2, active bacterial/viral/fungal/parasitic infection, or more than two α-globin gene deletions.
    Billing Rule

    Replacement and Infusion Eligibility

    Lyfgenia is approved as a one-time dose within 6 months, and eligibility must remain valid at the time of infusion.

    • Replacement product requested because the original product was lost or damaged is not covered.
    • Confirm continued member eligibility immediately before infusion.
    A vaso-occlusive episode requiring hospitalization or multiple emergency department or urgent-care visits over 72 hours, with intravenous medication at each visit
    PriapismPriapism requiring any level of medical attention
  3. Chart notes document at least four severe vaso-occlusive crises in the 2 years prior to screening while the member was adhering to previous SCD therapy.≥4 crises in the prior 2 years
  4. The member has failed to match with a hematopoietic stem cell donor.
  5. The member has tried and failed other sickle cell disease treatment, such as hydroxyurea, Adakveo, Oxbryta, or Endari, up to the maximally indicated dose for at least 6 months, with dates of use documented.Failure after ≥6 months at the maximally indicated dose
  6. The member has not received a prior allogeneic or autologous hematopoietic stem cell transplant.
  7. The member is not being considered for another gene or investigational therapy for sickle cell disease.
  8. A provider attests that the member is an appropriate candidate for hematopoietic stem cell transplantation.
  9. The member does not have renal impairment or advanced liver impairment, documented with current renal and liver function tests.Creatinine clearance >70 mL/min/1.73 m²

    Advanced liver impairment includes ALT >3 times the upper limit of normal; direct bilirubin >2.5 times the upper limit of normal; baseline PT/INR >1.5 times the upper limit of normal; cirrhosis; bridging fibrosis; or active hepatitis.

  10. For female members, a negative serum pregnancy test is confirmed.
  11. Current HIV-1 and HIV-2 screening is negative, with no active HIV-1 or HIV-2.
  12. The member has no active bacterial, viral, fungal, or parasitic infection.
  13. Lyfgenia is approved and administered as a one-time dose within 6 months, and the member remains eligible at the time of infusion.One dose within 6 months

    Replacement requests for lost or damaged product are not covered.